2022 American Transplant Congress
An Interventional Study Using Cell-Mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multi-Center Study
*Purpose: There are limited interventional studies using CMV cell-mediated immunity to guide the duration of antiviral prophylaxis. We aimed to use CMV CMI to guide…2022 American Transplant Congress
Cmv-Specific Cell-Mediated Immune Reconstitution in High-Risk Hematopoietic Cell Transplant Recipients Receiving Letermovir Prophylaxis
*Purpose: In the absence of antiviral prophylaxis following Hematopoietic Cell Transplant (HCT), the incidence of clinically significant cytomegalovirus reactivation (cCMV) is 30% in CMV seropositive…2022 American Transplant Congress
Evaluation of Prophylactic Valganciclovir Dosing in Kidney Transplant Recipients at an Urban Transplant Institution
*Purpose: Dosing and duration of cytomegalovirus (CMV) prophylaxis with valganciclovir (VGC) in kidney transplant (KT) recipients is variable by transplant center. Prior studies have shown…2022 American Transplant Congress
Incidence of Urinary Tract Infection or Asymptomatic Bacteriuria in Kidney Transplant Recipients with Sulfamethoxazole-Trimethoprim vs. Pentamidine for Pneumocystis Jiroveci Pneumonia Prophylaxis
University Health, San Antonio, TX
*Purpose: To compare the incidence of urinary tract infection (UTI) or asymptomatic bacteriuria (ASB) post-kidney transplant (KT) with multiple Pneumocystis jiroveci pneumonia (PJP) prophylaxis regimens*Methods:…2022 American Transplant Congress
Does a Second Transplant Increase the Risk for CMV Infection? An Evaluation of the Incidence of CMV Viremia in the Previously Transplanted Kidney Recipient
*Purpose: Cytomegalovirus (CMV) viremia is a common complication of kidney transplant recipients (KTR) with significant morbidity/mortality. Patients who receive multiple transplants are potentially at a…2022 American Transplant Congress
Preemptive Therapy for Cytomegalovirus (CMV) Disease Prevention in High-Risk CMV Donor Seropositive Recipient Seronegative (D+/R-) Liver Transplant Recipients in a Real-World Setting
*Purpose: Preemptive therapy (PET) has demonstrated superiority to antiviral prophylaxis for prevention of cytomegalovirus (CMV) disease in CMV donor seropositive/recipient seronegative (D+R-) liver transplant recipients …2022 American Transplant Congress
Comparison of Cephalexin and Ciprofloxacin Prophylaxis for Urinary Tract Infection in Kidney Transplant Recipients
Transplant Institute, Henry Ford Hospital, Detroit, MI
*Purpose: Compare efficacy and safety outcomes of patients (pts) that received alternative agents as prophylaxis (ppx) for urinary tract infection (UTI) after kidney transplant (KT)…2022 American Transplant Congress
Early versus Delayed Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
1Pharmacy, Houston Methodist Hospital, Houston, TX, 2Pharmacy, Nebraska Medicine, Omaha, NE
*Purpose: The purpose of this study is to determine the effect of delaying cytomegalovirus (CMV) prophylaxis to day of discharge or post-operative day (POD) 7…2022 American Transplant Congress
Donor-Derived Carbapenem-Resistant Gram-Negative Infections: Risk Mitigation Strategy in Solid Organ Transplant Improves Recipients Safety and Could Expand Donor Pool
*Purpose: We implemented an Active Surveillance System (ASS) to mitigate the risk of unexpected carbapenem-resistant Gram-negative (CRGN) donor-derived infection (DDI) in solid organ transplant recipient…2022 American Transplant Congress
Comparison of Perioperative Antibiotic Prophylaxis Regimens on Surgical Site Infections in Pancreas Transplant Recipients
*Purpose: Pancreas transplant recipients are at high risk of surgical site infection (SSI), with rates ranging from 9-45%. Several risk factors for SSI have been…
- 1
- 2
- 3
- …
- 14
- Next Page »